The FDA on June 21, 2024, granted accelerated approval to KRAZATI® (Adagrasib) plus Cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic ColoRectal Cancer (CRC), as determined by an FDA-approved test, who have received prior treatment with Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-based chemotherapy. KRAZATI® is a product of Mirati Therapeutics, Inc.
Bottom Ad
Advertisement
Subscribe
